|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Oxaliplatin,tetraplatin,cisplatin and carboplatin:sepctrum of activity in drug resistant cell lines of the national cancer institutes anticancer drug screen panel显示文摘 | Ortuzar W Alvarez M | 1996 | Biochem Pharmacd1996，52，12： | 1 |
| 2 | Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the national cancer institute' s anticancer drug screen panel 显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 3 | Complete remission seven years after treatment for metastatic malignant melanoma 显示文摘 | Borel C Rixe O | 1996 | Cancer1996，77，： | 1 |
| 4 | Randomized phase Ⅲ trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane显示文摘 | Sparano JA Vrdoljak E Rixe O | 2010 | J Clin Oncol2010，28，20： | 1 |
| 5 | Sunitinib malate 显示文摘 | IZZEDINE H BUHAESCUL I RIXE O | 2007 | Cancer Chemother Pharmacol2007，60，3： | 1 |
| 6 | Axltinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study 显示文摘 | RIXE O BUKOWSKI RM MICHAELSON MD | 2007 | Lancet Oncol2007，8，11： | 1 |
| 7 | Hypertension as a predictive factor of Sunitinib activity 显示文摘 | Rixe O Billemont B hzedine H | 2007 | Ann On col2007，18，6： | 1 |
| 8 | Oxaliplatin,tetraplatin,cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel显示文摘 | RIXE O ORTUZAR W ALVAREZ M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 9 | Oxaliplatin,tetraplatin,cisplatin and carboplatin:spectrum of activity in drug-resistant cell lines of the National Cancer Institute's Anticancer Drug Screen Panel显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Bioehem Pharmaeol1996，52，12： | 1 |
| 10 | Telomeres, telomerase and cancer显示文摘 | Soria J C Rixe O | 1977 | Bull Cancer1977，84，10： | 1 |
| 11 | Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer:a phase Ⅱ study显示文摘 | Rixe O Bukowski RM Michaelson MD | 2007 | Lancet Oncol2007，8，11： | 1 |
| 12 | Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study 显示文摘 | Rixe O Bukowski RM Miehaelson MD | 2007 | Lancet2007，8，11： | 1 |
| 13 | Axitinib trealment in patients with cytokine-refractory metastatic renal-cell cancer:a phase Ⅱ study显示文摘 | Rixe O Bukowaki RM Miehaelson MD | 2007 | Lancet Oncol2007，8，11： | 1 |
| 14 | Axitinib (AG-013736)显示文摘 | Kelly RJ Rixe O | | 0，，： | 1 |
| 15 | Renal toxicity of targeted therapies显示文摘 | Kelly RJ Billemont B Rixe O | 2009 | Targ Oncol2009，4，2： | 1 |
| 16 | Oxaliplatin,tetralatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the nation cancer institute's anticancer drug screen panel 显示文摘 | Rixe O Ortuzar W Alvarez M | 1996 | Biochem Pharmacol1996，52，12： | 1 |
| 17 | Axitinib (AG-013736)显示文摘 | Kelly RJ Rixe O | | 0，，： | 1 |
| 18 | Oxaliplatin, tetraplatin, cisplatin in drug-resistant cell lines of the National cancer Institute, Anticancer Drug Screen panel显示文摘 | Ortuzar W Alvarez M | 1996 | Bioehem Pharmarol1996，52，： | 1 |
| 19 | Axitinib treatment in patients with eytokine-refractory metastatic renal cell cancer:a phase Ⅱ study显示文摘 | Rixe O Bukowski RM Michaelson MD | 2007 | Lancet Oncol2007，8，11： | 1 |
| 20 | Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma treated by biochemotherapy:a retrospective study显示文摘 | Mouawad R Rixe O Meric JB | 2002 | Cytokines Cell Mol Ther2002，7，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员